LaBarre Michael J.'s Form 4/A amendment
AmendedHalozyme Therapeutics, Inc. (HALO) · filed Apr 19, 2023
- Accession no.
- 0001415889-23-006738
- Filed
- Apr 19, 2023
- Trade date
- Feb 27, 2023
- Filing delay
- 51 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Feb 28, 2023
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $147.9K. It was filed 51 days after the trade.
This amendment replaces 0001415889-23-003487 (filed Feb 28, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LaBarre Michael J.CIK 0001507174 | Officer (SVP, CHIEF TECHNICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2023 | Common Stock | MOption exerciseAcquired | +2,984 | $18.41 | +$54,935.44 | 144,895 | Direct | |
| Feb 27, 2023 | Common Stock | SSaleDisposed | −2,984 | $49.55F3 | −$147,857.2 | 141,911 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2023 | Common Stock | MOption exerciseDisposed | −2,984 | $0.00 | $0 | 37,505 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2
This amendment is being filed to include the option exercise information in Tables I and II and to update the information in Table I, Column 5.
- F3
Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.36 to $49.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.
- F4
This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.